The effects of levetiracetam on urinary 15f-2t-isoprostane levels in epileptic patients.
OBJECTIVE
We aimed to investigate the effects of levetiracetam on oxidative stress which is one of the new antiepileptic drugs in epileptic patients.


METHODS
The study consisted of 21 patients with cryptogenic partial epilepsy. We determined the urinary 15F-2t-isoprostane levels of the 30 patients which is a marker of oxidative stress. Morning urine samples were collected from the patients before beginning LEV and after 3 months treatment. Of these patients 9 were excluded from the study that had seizure history in the last 1 month. Urinary levels of 15-F2t-isoprostane determined by ELISA initially and after 3 months treatment for each patient.


RESULTS
Mean age of the 21 patients was 29.6, of these 11 were females and 10 males. Mean urinary 15F-2t-isoprostane level of the patients was 876 ± 447 ng/mg Cr before the treatment of LEV. After 3 months treatment the mean 15F-2t-isoprostane level of the patients was 1560 ± 630. The patients had significantly higher levels of urinary 15F-2t-isoprostane when compared with initial levels (p = 0.025).


CONCLUSIONS
Our results showed the increase of urinary 15F-2t-isoprostane levels in epileptic patients whom were treated with LEV which may indicate that LEV induces the oxidative stress in epileptic patients.
Ozden
Hilmi
H
Eskişehir Osmangazi University, Medical Faculty, Department of Anatomy, Eskisehir, Turkey.
Kabay
Sibel Canbaz
SC
Toker
Aysun
A
Ustüner
Mehmet Cengiz
MC
Ozbayer
Cansu
C
Ustüner
Derya
D
Günes
Hasan Veysi
HV
D000328:Adult; D000927:Anticonvulsants / Q000008:administration & dosage*; D015415:Biomarkers / Q000652:urine; D015237:Dinoprost / Q000031:analogs & derivatives; D004828:Epilepsies, Partial / Q000188:drug therapy / Q000378:metabolism; D004827:Epilepsy / Q000188:drug therapy* / Q000378:metabolism*; D005260:Female; D006801:Humans; D028421:Isoprostanes / Q000652:urine*; D000077287:Levetiracetam; D008297:Male; D018384:Oxidative Stress / Q000187:drug effects*; D010889:Piracetam / Q000008:administration & dosage / Q000031:analogs & derivatives*
D000927:Anticonvulsants; D015415:Biomarkers; D028421:Isoprostanes; C075750:8-epi-prostaglandin F2alpha; D000077287:Levetiracetam; D015237:Dinoprost; D010889:Piracetam